QQQ   418.82 (+1.01%)
AAPL   165.84 (+0.51%)
MSFT   400.96 (+0.46%)
META   481.73 (+0.14%)
GOOGL   156.28 (+1.42%)
AMZN   177.23 (+1.49%)
TSLA   142.05 (-3.40%)
NVDA   795.18 (+4.35%)
AMD   148.64 (+1.36%)
NIO   4.00 (+5.26%)
BABA   70.68 (+2.33%)
T   16.31 (-1.21%)
F   12.88 (+6.10%)
MU   109.12 (+2.20%)
GE   150.19 (+1.44%)
CGC   7.85 (-1.01%)
DIS   111.99 (-0.55%)
AMC   3.42 (+8.23%)
PFE   26.26 (+1.00%)
PYPL   63.19 (+1.41%)
XOM   120.56 (+0.57%)
QQQ   418.82 (+1.01%)
AAPL   165.84 (+0.51%)
MSFT   400.96 (+0.46%)
META   481.73 (+0.14%)
GOOGL   156.28 (+1.42%)
AMZN   177.23 (+1.49%)
TSLA   142.05 (-3.40%)
NVDA   795.18 (+4.35%)
AMD   148.64 (+1.36%)
NIO   4.00 (+5.26%)
BABA   70.68 (+2.33%)
T   16.31 (-1.21%)
F   12.88 (+6.10%)
MU   109.12 (+2.20%)
GE   150.19 (+1.44%)
CGC   7.85 (-1.01%)
DIS   111.99 (-0.55%)
AMC   3.42 (+8.23%)
PFE   26.26 (+1.00%)
PYPL   63.19 (+1.41%)
XOM   120.56 (+0.57%)
QQQ   418.82 (+1.01%)
AAPL   165.84 (+0.51%)
MSFT   400.96 (+0.46%)
META   481.73 (+0.14%)
GOOGL   156.28 (+1.42%)
AMZN   177.23 (+1.49%)
TSLA   142.05 (-3.40%)
NVDA   795.18 (+4.35%)
AMD   148.64 (+1.36%)
NIO   4.00 (+5.26%)
BABA   70.68 (+2.33%)
T   16.31 (-1.21%)
F   12.88 (+6.10%)
MU   109.12 (+2.20%)
GE   150.19 (+1.44%)
CGC   7.85 (-1.01%)
DIS   111.99 (-0.55%)
AMC   3.42 (+8.23%)
PFE   26.26 (+1.00%)
PYPL   63.19 (+1.41%)
XOM   120.56 (+0.57%)
QQQ   418.82 (+1.01%)
AAPL   165.84 (+0.51%)
MSFT   400.96 (+0.46%)
META   481.73 (+0.14%)
GOOGL   156.28 (+1.42%)
AMZN   177.23 (+1.49%)
TSLA   142.05 (-3.40%)
NVDA   795.18 (+4.35%)
AMD   148.64 (+1.36%)
NIO   4.00 (+5.26%)
BABA   70.68 (+2.33%)
T   16.31 (-1.21%)
F   12.88 (+6.10%)
MU   109.12 (+2.20%)
GE   150.19 (+1.44%)
CGC   7.85 (-1.01%)
DIS   111.99 (-0.55%)
AMC   3.42 (+8.23%)
PFE   26.26 (+1.00%)
PYPL   63.19 (+1.41%)
XOM   120.56 (+0.57%)
NASDAQ:ALXO

ALX Oncology (ALXO) Stock Price, News & Analysis

$14.23
-1.37 (-8.78%)
(As of 05:20 PM ET)
Today's Range
$13.88
$15.66
50-Day Range
$10.72
$16.79
52-Week Range
$3.94
$17.42
Volume
287,275 shs
Average Volume
433,281 shs
Market Capitalization
$711.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.83

ALX Oncology MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
28.7% Upside
$18.83 Price Target
Short Interest
Bearish
11.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.60mentions of ALX Oncology in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$933,000 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.33) to ($2.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.74 out of 5 stars

Medical Sector

681st out of 907 stocks

Pharmaceutical Preparations Industry

316th out of 428 stocks

ALXO stock logo

About ALX Oncology Stock (NASDAQ:ALXO)

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

ALXO Stock Price History

ALXO Stock News Headlines

$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
ALX Oncology: Trying To Justify The Hype
ENPH, OCUL and ITCI are among after hour movers
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Alx Oncology CEO buys $49.7k in company shares
ALXO Apr 2024 7.000 put
ALXO Apr 2024 19.000 call
ALXO Apr 2024 14.000 put
ALX Oncology just downgraded at Stifel, here's why
See More Headlines
Receive ALXO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ALX Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
4/22/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALXO
Fax
N/A
Employees
72
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.83
High Stock Price Target
$27.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+21.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-160,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.81 per share

Miscellaneous

Free Float
24,850,000
Market Cap
$772.50 million
Optionable
Optionable
Beta
1.58
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Corey S. Goodman Ph.D. (Age 72)
    Executive Chairman
    Comp: $84k
  • Mr. Jason W. LettmannMr. Jason W. Lettmann (Age 47)
    CEO & Director
    Comp: $60.5k
  • Dr. Jaume Pons Ph.D. (Age 57)
    Founder, President, Director & Chief Scientific Officer
    Comp: $856.29k
  • Mr. Peter S. Garcia M.B.A.Mr. Peter S. Garcia M.B.A. (Age 62)
    Chief Financial Officer
    Comp: $631.11k
  • Dr. Sophia Randolph M.D. (Age 56)
    Ph.D., Chief Medical Officer & Director
    Comp: $637.24k
  • Dr. Michael Chang Ph.D.
    Vice President of Operations
  • Ms. Shelly Pinto (Age 47)
    Senior VP of Finance & Chief Accounting Officer
    Comp: $508.26k
  • Dr. Christopher Byrd J.D.
    Ph.D., General Counsel
  • Dr. Athanasios Tsiatis M.D.
    Senior Vice President of Clinical Development
  • Dr. Lin Yeong-Liang M.D.
    M.S., Senior Vice President of Drug Safety & Pharmacovigilance

ALXO Stock Analysis - Frequently Asked Questions

Should I buy or sell ALX Oncology stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ALX Oncology in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALXO shares.
View ALXO analyst ratings
or view top-rated stocks.

What is ALX Oncology's stock price target for 2024?

7 analysts have issued 12-month price objectives for ALX Oncology's stock. Their ALXO share price targets range from $11.00 to $27.00. On average, they expect the company's stock price to reach $18.83 in the next year. This suggests a possible upside of 28.7% from the stock's current price.
View analysts price targets for ALXO
or view top-rated stocks among Wall Street analysts.

How have ALXO shares performed in 2024?

ALX Oncology's stock was trading at $14.89 at the beginning of the year. Since then, ALXO stock has decreased by 1.7% and is now trading at $14.63.
View the best growth stocks for 2024 here
.

Are investors shorting ALX Oncology?

ALX Oncology saw a increase in short interest in March. As of March 31st, there was short interest totaling 3,120,000 shares, an increase of 7.2% from the March 15th total of 2,910,000 shares. Based on an average daily volume of 389,200 shares, the days-to-cover ratio is currently 8.0 days. Approximately 11.5% of the company's stock are short sold.
View ALX Oncology's Short Interest
.

When is ALX Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ALXO earnings forecast
.

How were ALX Oncology's earnings last quarter?

ALX Oncology Holdings Inc. (NASDAQ:ALXO) issued its earnings results on Thursday, March, 7th. The company reported ($0.93) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by $0.09.

What ETF holds ALX Oncology's stock?

Inspire Small/Mid Cap ETF holds 33,156 shares of ALXO stock, representing 0.23% of its portfolio.

What other stocks do shareholders of ALX Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ALX Oncology investors own include Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Innovative Industrial Properties (IIPR), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and

When did ALX Oncology IPO?

ALX Oncology (ALXO) raised $128 million in an IPO on Friday, July 17th 2020. The company issued 8,000,000 shares at $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor acted as the underwriters for the IPO and LifeSci Capital was co-manager.

Who are ALX Oncology's major shareholders?

ALX Oncology's stock is owned by many different retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.20%). Insiders that own company stock include Jason Lettmann, Jaume Pons, Lsv Associates, Llc, Peter S Garcia, Peter S Garcia, Shelly Pinto and Sophia Randolph.
View institutional ownership trends
.

How do I buy shares of ALX Oncology?

Shares of ALXO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALXO) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners